ABE8 Beta Globin Base Editing for High-Efficiency Sickle Cell Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating sickle cell disease (SCD) focus on managing symptoms rather than addressing the underlying genetic mutations, and there is an urgent need for effective genetic editing technologies to correct these mutations.
Innovation Solution
A modified adenosine deaminase base editor (ABEF8) is used to edit beta globin polynucleotides associated with SCD, targeting specific single nucleotide polymorphisms (SNPs) using guide RNAs and a fusion protein with a programmable DNA binding domain to achieve high efficiency A·T to G·C alterations, thereby correcting the genetic cause of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used to manage SCD symptoms, then symptom management is maintained, but the underlying genetic mutations remain uncorrected
Solution Approach 1:
The patent modifies the adenosine deaminase base editor by introducing specific amino acid substitutions (e.g., Y147R, Q154R, Y123H, Q154S, V82S, T166R) to enhance editing efficiency. These parameter changes in the enzyme's amino acid sequence directly improve its ability to correct sickle cell mutations, achieving over 60-70% correction efficiency while maintaining targeted genetic modification capability
Solution Approach 2:
The invention creates a composite molecular system by fusing the adenosine deaminase enzyme with a programmable DNA binding domain (such as Cas9 or transcription activator-like effector nucleases). This composite structure combines the editing capability of adenosine deaminase with the target-specific binding ability of the DNA binding domain, enabling precise and efficient correction of sickle cell disease mutations
2Productivity
If base editing is used to correct genetic mutations, then mutation correction efficiency is improved, but the complexity of the editing system increases
Solution Approach 1:
The patent merges multiple functional domains into a single fusion protein: the adenosine deaminase editing domain, the programmable DNA binding domain (Cas9 or TALEN), and a guide RNA recognition domain. This unified structure eliminates the need for separate delivery and coordination of multiple components, simplifying the overall system while achieving high correction efficiency through the synergistic function of integrated domains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves unprecedented efficiency (>60-70%) in correcting the genetic mutations associated with SCD, potentially leading to improved clinical outcomes by altering the HBB polypeptide sequence to alleviate disease symptoms.
Implementation Method 1
a fusion protein comprising a polynucleotide programmable DNA binding domain and at least one base editor domain that is an adenosine deaminase variant comprising an alteration at amino acid position 82 and/or 166
Data Source
AI summary
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.